Phyton shares new article published by iScience that demonstrates that QS-21 produced via plant cell culture for saponin-derived vaccine adjuvants can be commercially produced in a sustainable way

FOR IMMEDIATE RELEASE

Phyton shares new article published by iScience that demonstrates that QS-21 produced via plant cell culture for saponin-derived vaccine adjuvants can be commercially produced in a sustainable way

Delta, British Columbia, March 14, 2014 – Phyton Biotech is pleased to announce a recent publication by iScience showcasing the successful application of its plant cell fermentation platform to derive an important compound. A compound traditionally extracted from the rare Quillaja tree and used in an adjuvant for a vaccine has been successfully produced in partnership with Phyton through the application of their plant cell fermentation technology (PCF). The compound called QS-21 is another example of how Phyton continues to evolve their technology to derive needed compounds for use in sustainable commercial production.

Learn about the chemical and biological characterization of QS-21, and Phyton’s revolutionary in vitro platform to develop saponin-derived vaccine adjuvants in the recent article published by iScience.

For inquiries and partnership opportunities, please contact:

Stephen Ball
VP of Business Development
[email protected]
902-393-4245

About Phyton Biotech LLC.

Phyton Biotech LLC. is a leading provider of specialized services in the purification and isolation of natural active pharmaceuticals. With a rich history spanning over two decades, Phyton Biotech is dedicated to supporting advancements in pharmaceutical research and development. The recent acquisition of the Controlled Substances Dealers License underscores Phyton Biotech’s commitment to exploring new frontiers in drug development, particularly in the emerging field of psilocin and psilocybin. Learn more at phytonbiotech.com.